NIRMATRELVIR; RITONAVIR - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for nirmatrelvir; ritonavir and what is the scope of patent protection?
Nirmatrelvir; ritonavir
is the generic ingredient in one branded drug marketed by Pfizer and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.Nirmatrelvir; ritonavir has fifty-two patent family members in thirty-four countries.
One supplier is listed for this compound.
Summary for NIRMATRELVIR; RITONAVIR
International Patents: | 52 |
US Patents: | 2 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 21 |
DailyMed Link: | NIRMATRELVIR; RITONAVIR at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for NIRMATRELVIR; RITONAVIR
Generic Entry Date for NIRMATRELVIR; RITONAVIR*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for NIRMATRELVIR; RITONAVIR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Kanecia Obie Zimmerman | Phase 2 |
National Taiwan University Hospital | Phase 2/Phase 3 |
Karolinska University Hospital | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for NIRMATRELVIR; RITONAVIR
US Patents and Regulatory Information for NIRMATRELVIR; RITONAVIR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | PAXLOVID (COPACKAGED) | nirmatrelvir; ritonavir | TABLET;ORAL | 217188-002 | May 25, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Pfizer | PAXLOVID (COPACKAGED) | nirmatrelvir; ritonavir | TABLET;ORAL | 217188-001 | May 25, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Pfizer | PAXLOVID (COPACKAGED) | nirmatrelvir; ritonavir | TABLET;ORAL | 217188-001 | May 25, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Pfizer | PAXLOVID (COPACKAGED) | nirmatrelvir; ritonavir | TABLET;ORAL | 217188-001 | May 25, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for NIRMATRELVIR; RITONAVIR
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
China | 114466838 | 含腈的抗病毒化合物 (Nitrile-containing antiviral compounds) | ⤷ Sign Up |
South Africa | 202204781 | NITRILE-CONTAINING ANTIVIRAL COMPOUNDS | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2021250648 | ⤷ Sign Up | |
European Patent Office | 3953330 | COMPOSÉS ANTIVIRAUX CONTENANT DU NITRILE (NITRILE-CONTAINING ANTIVIRAL COMPOUNDS) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |